Patient Characteristics, Skeletal Related Events (SRE) And Renal Impairment (RI) In Patients With Multiple Myeloma (MM): A Patient Chart Audit In EU5

Mateos, M. V.; Cavo, Michèle; Fink, Louis M.; Koneswaran, N; Giannopoulou, Christina; Niepel, Daniela; Gonzalez‐McQuire, Sebastian; Intorcia, Michele

doi:10.1016/j.jval.2017.08.093

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A population-based study from the United Kingdom found a 32% rate of SREs among patients with MM who were newly diagnosed between 2004 and 2009 [30]. A 2016 chart audit of medical records of patients with newly diagnosed MM from France, Germany, Italy, Spain, and the United Kingdom found that 26% of patients had ≥1 new SRE between diagnosis and disease progression [31]. An analysis of the Truven Health MarketScan Commercial Claims and Medicare Supplemental databases found that 58% of United States patients with MM diagnosed between 2005 and 2011 experienced an SRE during the follow-up period [14].…”

Section: Discussionmentioning

confidence: 99%

Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data

Kim

Bhatta

Cyprien³

et al. 2019

Journal of Bone Oncology

View full text Add to dashboard Cite

Skeletal-related events (SREs) are common bone complications in multiple myeloma (MM). However, there are few real-world reports of their incidence. In this study, a database of oncology electronic health records was linked to administrative claims data. Patients identified were aged ≥18 years and newly diagnosed with MM, had ≥1 clinic visit within 1 month of diagnosis, and ≥1 year of follow-up after diagnosis. The study period was January 1, 2011 to December 31, 2016. 343 patients were included, 35% of whom had a baseline history of any SRE. During a median follow-up of 25.7 months, 34% of patients experienced SREs after diagnosis. Median time to SRE was 167 days. Among patients experiencing an SRE, 68% had an SRE within the first year. The incidence rate of SREs at 1 year following MM diagnosis for patients with baseline history was 103/100 person-years (PY) versus 16/100PY for patients without baseline history. SRE incidence rates within 3 months of initiating a line of therapy increased with subsequent lines (line 1: 81/100PY, line 2: 118/100PY, line 3: 150/100PY). Risk of SREs was similar across different anti-MM regimens, including proteasome inhibitor-based regimens. These results highlight the importance of continued surveillance and management of MM-associated bone disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data

Kim

Bhatta

Cyprien³

et al. 2019

Journal of Bone Oncology

View full text Add to dashboard Cite

show abstract

“…The data sets generated and analysed during the current study are not publicly available, but they are available from the corresponding author on reasonable request. This study has been previously published as an abstract [51].…”

Section: Fundingmentioning

confidence: 99%

Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review

Mateos

Fink²,

Koneswaran³

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: Bone complications (pathologic fracture, spinal cord compression, surgery to bone and radiation to bone) are a common problem in patients with multiple myeloma (MM). We set out to provide insights into the real-world burden of bone complications in patients with newly diagnosed MM (NDMM). Methods: We conducted a retrospective review of medical charts of patients with NDMM whose disease had progressed following first-line treatment in the 3 months before data collection in 2016 in five European countries (France, Germany, Italy, Spain and the United Kingdom). Results: The aggregated study population included 813 patients. Bone pain commonly led to MM diagnosis (63%) and 74% of all patients had two or more bone lesions at initiation of first-line treatment. Furthermore, 26% of patients experienced a new bone complication between MM diagnosis and disease progression following first-line treatment, despite 75% of individuals receiving bisphosphonates. Most bone complications (52%) occurred in the period before initiation of first-line treatment (mean duration: 2.3 months) and more than half of patients (56%) who experienced a new bone complication were hospitalised. Analgesics were used more frequently in patients with bone complications than in those without them (76% vs 50%, respectively). Furthermore, 51% of patients had renal impairment by the time first-line treatment was started. Overall, 25% of patients did not receive bisphosphonates for prevention of bone complications and one in four of those with renal impairment at initiation of first-line treatment did not receive bisphosphonates.Conclusions: Bone complications are common in patients with NDMM. They are frequently associated with hospitalization and analgesic use. Data from this study, conducted in the era of novel anti-myeloma therapies and before the approval of denosumab for use in patients with MM, suggest that although most patients (75%) received bisphosphonates, use of anti-resorptive therapy for prevention of bone complications may be suboptimal in patients with NDMM, irrespective of renal function.

show abstract

Patient Characteristics, Skeletal Related Events (SRE) And Renal Impairment (RI) In Patients With Multiple Myeloma (MM): A Patient Chart Audit In EU5

Cited by 2 publications

References 0 publications

Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data

Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data

Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review

Contact Info

Product

Resources

About